Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297852 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL29922417 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL16432729 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL444477 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL24017118 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL8934995 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL24017129 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL11454917 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL3974471 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 | |
| SCHEMBL30514149 | 1.00 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9523002-B2 | Moisture curable organopolysiloxane compositions | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140316059-A1 | MOISTURE CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2014-10-23 | — | — | US | disclosed |
| US-20120065308-A1 | MOISTURE CURABLE ORGANOPOLYSILOXANE COMPOSITION | MOMENTIVE PERFORMANCE MATERIALS INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | PISGAH LABORATORIES, INC. | 2012-02-02 | — | — | US | disclosed |
| EP-1918294-B1 | Nanostructured Particles, Phase Change Inks Including Same and Methods for Making Same | XEROX CORP (US) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | COMT, SLC6A3, SLC6A2 | OPRM1 11/4885CYP2D6 12/4885SPHK1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.